The risks and benefits of antidepressant treatment for youth depression

References

• US Food and Drug Administration, Relationship between psychotropic drugs and pediatric suicidality. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4065b1‐10‐TAB08‐Hammads‐Review.pdf
   Google Scholar
• Committee on Safety of Medicines. Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/SSRIfinal.pdf (accessed 6/15/2005)
   Google Scholar
• US Food and Drug Administration. Class Suicidality Labeling Language for Antidepressants http://www.fda.gov/cder/drug/antidepressants/PI_template.pdf (accessed 7/01/05)
   Google Scholar
• US Food and Drug Administration:. Medication Guide: About Using Antidepressants in Children and Teenagers. http://www.fda.gov/cder/drug/antidepressants/MG_template.pdf (accessed 12/21/2004)
   Google Scholar
• Gunnell D., Saperia J., Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta‐analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330: 385
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Events by Trial Table (corrected). http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4065B1_28_Handout‐Events‐by‐trial‐table‐Corrected.pdf (accessed 3/07/2005)
   Google Scholar
• March J. S., Silva S., Petrycki S., Curry J., Wells K., Fairbank J. Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003; 42: 531–42
   PubMed Web of Science ®Google Scholar
• March J., Silva S., Petrycki S., Curry J., Wells K., Fairbank J. Fluoxetine, cognitive‐behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807–20
   PubMed Web of Science ®Google Scholar
• Mann J. J., Waternaux C., Haas G. L., Malone K. M. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999; 156: 181–9
   PubMed Web of Science ®Google Scholar
• Mann J. J., Brent D. A., Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001; 24: 467–77
   PubMed Web of Science ®Google Scholar
• Jick H., Kaye J. A., Jick S. S. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338–43
   PubMed Web of Science ®Google Scholar
• Ludwig J., Marcotte D. E. Anti‐depressants, suicide, and drug regulation. J Pol Anal Manage 2005; 24: 249–72
   PubMed Web of Science ®Google Scholar
• Olfson M., Shaffer D., Marcus S. C., Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82
   PubMed Web of Science ®Google Scholar
• Valuck R. J., Libby A. M., Sills M. R., Giese A. A., Allen R. R. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity‐adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119–32
   PubMed Web of Science ®Google Scholar
• Webster D. W., Vernick J. S., Zeoli A. M., Manganello J. A. Association between youth‐focused firearm laws and youth suicides. JAMA 2004; 292: 594–601
   PubMed Web of Science ®Google Scholar
• Hall W. D., Mant A., Mitchell P. B., Rendle V. A., Hickie I. B., McManus P. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008
   PubMed Web of Science ®Google Scholar
• Martinez C., Rietbrock S., Wise L., Ashby D., Chick J., Moseley J. Antidepressant treatment and the risk of fatal and non‐fatal self harm in first episode depression: nested case‐control study. BMJ 2005; 330: 389
   PubMed Web of Science ®Google Scholar
• Jureidini J. N., Doecke C. J., Mansfield P. R., Haby M. M., Menkes D. B., Tonkin A. L. Efficacy and safety of antidepressants for children and adolescents.[erratum appears in BMJ. 2004 May 15;328:1170]. BMJ 2004; 328: 879–83
   PubMed Web of Science ®Google Scholar
• Whittington C. J., Kendall T., Fonagy P., Cottrell D., Cotgrove A., Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–5
   PubMed Web of Science ®Google Scholar
• Cheung A. H., Emslie G. J., Mayes T. L. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005; 46: 735–54
   PubMed Web of Science ®Google Scholar
• Emslie G. J., Rush A. J., Weinberg W. A., Kowatch R. A., Hughes C. W., Carmody T. A double‐blind, randomized, placebo‐controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7
   PubMed Web of Science ®Google Scholar
• Emslie G. J., Heiligenstein J. H., Wagner K. D., Hoog S. L., Ernest D. E., Brown E. Fluoxetine for acute treatment of depression in children and adolescents: a placebo‐controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205–15
   PubMed Web of Science ®Google Scholar
• Simeon J. G., Dinicola V. F., Ferguson H. B., Copping W. Adolescent depression: a placebo‐controlled fluoxetine treatment study and follow‐up. Progr Neuro‐Psychopharmacol Biol Psychiatry 1990; 14: 791–5
   PubMed Web of Science ®Google Scholar
• Wagner K. D., Ambrosini P., Rynn M., Wohlberg C., Yang R., Greenbaum M. S. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033–41
   PubMed Web of Science ®Google Scholar
• Wagner K. D., Robb A. S., Findling R. L., Jin J., Gutierrez M. M., Heydorn W. E. A randomized, placebo‐controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161: 1079–83
   PubMed Web of Science ®Google Scholar
• Keller M. B., Ryan N. D., Strober M., Klein R. G., Kutcher S. P., Birmaher B. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–72
   PubMed Web of Science ®Google Scholar
• Mandoki M. W., Tapia M. R., Tapia M. A., Sumner G. S., Parker J. L. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997; 33: 149–54
   PubMedGoogle Scholar
• Emslie G. J., Findling R. L., Yeung P. P., Kunz N. R., Li Y., Dum B. L. Efficacy and safety of venlafaxine extended release in children and adolescents with MDD. 157th Annual Meeting of the American Psychiatric Association. New York, N.Y 2004
   Google Scholar
• Emslie G. J., Findling R. L., Rynn M. A., Marcus R. N., Fernandes L. A., D'Amico M. F. Efficacy and safety of nefazadone in the treatment of adolescents with major depressive disorder. 42nd Annual Meeting of the National Institute of Mental Health: New Clinical Drug Evaluation Unit (NCDEU). Boca Raton, FL 2002
   Google Scholar
• Rynn M. A., Findling R. L., Emslie G. J., Marcus R. N., Fernandes L. A., D'Amico M. F. Efficacy and safety of nefazadone in adolescents with MDD. 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA 2002
   Google Scholar
• US Food and Drug Administration. Determination that serzone (nefazadone hydrochloride) was not withdrawn from sale for reasons of safety or effectiveness. http://www.fda.gov/ohrms/dockets/98fr/04‐23857.htm (accessed 3/05/2005)
   Google Scholar
• Sackett D. L., Straus S. E., Richardson W. S., Rosenberg W., Haynes R. B. Evidence‐based medicine: How to practice and teach EBM. Churchill Livingstone, Edinburgh; New York 2000
   Google Scholar
• McQuay H. J., Moore R. A. Using numerical results from systematic reviews in clinical practice. Ann Int Med 1997; 126: 712–20
   PubMed Web of Science ®Google Scholar
• Clerc G. E., Ruimy P., Verdeau‐Palles J. A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. International Clinical Psychopharmacology 1994; 9: 139–43
   PubMed Web of Science ®Google Scholar
• Dierick M., Ravizza L., Realini R., Martin A. A double‐blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 57–71
   PubMed Web of Science ®Google Scholar
• Costa e Silva J. Randomized, double‐blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998; 59: 352–7
   PubMed Web of Science ®Google Scholar
• Poirier M. F., Boyer P. Venlafaxine and paroxetine in treatment‐resistant depression. Double‐blind, randomised comparison. B J Psychiatry 1999; 175: 12–6
   PubMed Web of Science ®Google Scholar
• Silverstone P. H., Ravindran A. Once‐daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999; 60: 22–8
   PubMed Web of Science ®Google Scholar
• Brent D. A., Holder D., Kolko D., Birmaher B., Baugher M., Roth C. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997; 54: 877–85
   PubMed Web of Science ®Google Scholar
• Mufson L., Weissman M. M., Moreau D., Garfinkel R. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999; 56: 573–9
   PubMed Web of Science ®Google Scholar
• Mufson L., Dorta K. P., Wickramaratne P., Nomura Y., Olfson M., Weissman M. M. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004; 61: 577–84
   PubMed Web of Science ®Google Scholar
• Beck A. T., Rush A. J., Shaw B. F., Emery G. Cognitive Therapy of Depression. Guilford Press, New York, N.Y. 1979
   Google Scholar
• Brent D. A., Roth C., Holder D., Kolko D. J., Birmaher B., Johnson B. A. Psychosocial interventions for treating adolescent depression: a comparison of three psychosocial interventions. E. D Hibbs, P. S Jensen. American Psychiatric Press, Inc., Washington, DC 1996; 187–206
   Google Scholar
• Mufson L., Dorta K. P., Moreau D., Weissman M. M. Interpersonal psychotherapy for depressed adolescents. The Guilford Press, New York 2004
   Google Scholar
• Clarke G. N., Rohde P., Lewinsohn P. M., Hops H., Seeley J. R. Cognitive‐behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry 1999; 38: 272–9
   PubMed Web of Science ®Google Scholar
• Bridge J. A., Brent D. A. Adolescents with depression. [letter]. JAMA 2004; 292: 2578
   PubMedGoogle Scholar
• Martin A., Young C., Leckman J. F., Mukonoweshuro C., Rosenheck R., Leslie D. Age effects on antidepressant‐induced manic conversion. Arch Pediatr Adolesc Med 2004; 158: 773–80
   PubMed Web of Science ®Google Scholar
• Brent D. A., Perper J. A., Moritz G., Allman C., Friend A., Roth C. Psychiatric risk factors for adolescent suicide: a case‐control study. J Am Acad Child Adolesc Psychiatry 1993; 32: 521–9
   PubMed Web of Science ®Google Scholar
• Lewinsohn P. M., Rohde P., Seeley J. R. Adolescent suicidal ideation and attempts: prevalence, risk factors, and clinical implications. Clinical Psychology Science and Practice 1996; 3: 25–36
   Web of Science ®Google Scholar
• Pokorny A. D. Prediction of suicide in psychiatric patients. Report of a prospective study. Arch Gen Psychiatry 1983; 40: 249–57
   PubMed Web of Science ®Google Scholar